Drugs and Therapeutics Advisory Board Meeting
Thursday, January 13, 2022 8:30am-11am

Agenda

I. Call to Order
II. Roll Call
III. Welcome
IV. Agenda and Conflict of Interest Review
V. Approval of the Minutes
VI. Public Comments
VII. PDL Drug Appeals
   a. None at this meeting
VIII. New Drug Appeals (with discussion and vote)
   a. Qelbree (Viloxazine HCL Cap ER)-Michael Feld, MD
IX. Drug Class Review- Ryan Rodriguez, PharmD Clinical review
    (with discussion and vote)
   a. Antiasthmatics-Adrenergic
   b. Antiasthmatics-Anticholinergic
X. New Drug Initial Review-Ryan Rodriguez, PharmD (with
discussion and vote)
   a. Lybalvi (Olanzapine-Samidorphan L-malate)
   b. Invega Hafyera (Paliperidone Palmitate)
   c. Myfembree (Regugolix-Estradiol-Norethindrone Acetate)
   d. Qulipta (Atogepant)
XI. Future Agenda Preview -Sheri Dolan
XII. Provider Requested Reviews-Sheri Dolan
    a. None at this meeting
XIII. Department Update-Jose Jimenez
    The department is seeking doctors from central and southern
    Illinois to serve on our Drug Utilization Review board. If you
    know a physician you think fits the bill please send contact
    information to Sheri.
XIV. Adjournment
Call-In Information for this meeting can be found at the top of page: https://www2.illinois.gov/hfs/MedicalProviders/Pharmacy/Pages/ClassReviewSchedule.aspx

## Scheduled Speakers

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Product</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassandra Lickert, MD</td>
<td>Myfembree</td>
<td>Myovant Sciences, Inc.</td>
</tr>
<tr>
<td>Rudy Christian, DrPH</td>
<td>Lybalvi</td>
<td>Alkermes</td>
</tr>
<tr>
<td>Jenish Patel, PharmD.</td>
<td>Invega Hafyera</td>
<td>Janssen</td>
</tr>
<tr>
<td>Michael Feld, MD</td>
<td>Qelbree</td>
<td>Michael Feld, MD SC</td>
</tr>
<tr>
<td>Christopher Rhyne, MD</td>
<td>Qulipta</td>
<td>Diamond Headache Clinic</td>
</tr>
<tr>
<td><strong>George Vass, PharmD</strong></td>
<td>Qulipta</td>
<td>AbbVie</td>
</tr>
</tbody>
</table>

**George will speak as backup only if Dr. Rhyne cannot be present.**